75 results about "Obstructive lung disease" patented technology

The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

Embodiments of the disclosure can include biomarkers for systems, methods, and devices for detecting and identifying certain substances, such as chemicals, volatile organic compounds (VOCs), volatile gases (VGs), ketones, cannabis, controlled substances, pharmaceuticals, or anesthetics, in the exhaled breath of a subject or person in real-time; and further diagnosing, treating, and addressing one or more associated health conditions or diseases, including a virus, such as COVID-19, tuberculosis (TB), lung cancer, or chronic obstructive lung disease (COPD).

The invention provides a medicine for treating chronic obstructive pulmonary disease during stable period and a preparation method of the medicine. The medicine is prepared from astragalus membranaceus, polygonatum kingianum, radix glehniae, aster, earthworm, inula flower, cortex albiziae, salviae miltiorrhizae, ligusticum wallichii, bombyx batryticatus, poria cocos, ginger processed pinellia, honey-fried licorice root, rhizoma atractylodis macrocephalae, epimedium and rhodiola rosea. The medicine has the effects of strengthening spleen, freeing lung, tonifying kidney, regulating qi, eliminating phlegm, removing stasis, relieving cough and asthma, resolving depression and calming, can be used for achieving the effect of treating both symptoms and root cause of the chronic obstructive pulmonary disease during stable period, improving lung functions, relieving clinical symptoms and improving the living quality and prognosis of patients in the chronic obstructive pulmonary disease during stable period. The medicine composition has remarkable effect and no side effect on treatment of the chronic obstructive pulmonary disease during stable period.

The invention discloses a multi-electrode ablation device which comprises an electrode assembly, a guiding conduit, a handle and a connector. At least one cavity exists in the guiding conduit. The electrode assembly is arranged at the front end of the guiding conduit and penetrates through the guiding conduit through a line to be connected with the handle, the guiding conduit comprises one or more electrode groups and one or more detection devices, the electrode groups can exert electric energy, radio frequency energy, laser energy, high-density focused ultrasound or low-temperature ablation, and the detection devices are used for detecting temperature, impedance or tension. The handle is connected with the connector and one or more groups of electrode assemblies and comprises one or more control parts, and the control parts are used for controlling shrinkage, opening and energy of the electrode groups and can control the electrode assemblies to stretch out or retreat back to the guiding conduit. The connector is used for providing energy for electrodes. The device can be used for delivering direct current, alternating current and radio frequency energy to foci and can be used for non-medicine treatment of obstructive lung diseases.

The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary / respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.

Devices and methods for treating one or more pulmonary diseases while avoiding or minimizing injury to the esophagus and branches of the vagus nerve that run along the outside of the esophagus. The device includes at least one energy delivery element disposed on an elongate member and a means for protecting the esophagus and surrounding tissues, such as esophageal branches of the vagus nerve, during treatment. The energy delivery element is positionable to target at least one nerve in or around the tracheal wall when the elongate member is positioned in the trachea. Energy from the energy delivery element is delivered to the at least one nerve to treat pulmonary symptoms, conditions, and / or diseases, such as asthma, COPD, obstructive lung diseases, or other pulmonary diseases, while the protection means protects the esophagus and surrounding tissues from permanent damage.

The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and / or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.

The present invention belongs to the technical field of medicine food homology formulas and new resource food, and specifically provides a chronic obstructive pulmonary disease specific full nutritional formula food. The formula is based on the requirements of the "General rules for formula food with special medical purposes" and is combined with the physical characteristics of chronic obstructive pulmonary patients, and a variety of medicinal and edible traditional Chinese medicines are reasonably combined according to the quintessence theory of traditional Chinese medicine. The food is prepared from various edible and medicinal Chinese herb extracts extracted with pre-hydrolysis SBE technology, various microencapsulated probiotics, short peptides extracted through biological enzymolysis, prebiotics, amino acids, carbohydrates, healthy functional fats, vitamins and minerals. According to the invention, the obtained formula food can be adopted as the sole nutrition source to meet the nutritional needs of the chronic obstructive pulmonary disease patients, and can further provide effects of spleen strengthening and lung tonifying, heat-clearing and detoxicating, spleen-stomach invigorating and Qi replenishing, phlegm dissipating and cough stopping, lung tonifying and heat clearing, and chronic obstructive pulmonary disease preventing and curing.

The invention discloses medical composition containing active component of (3S, 2'R)-3-(2'-hydroxyl-2'-cyclopentyl-2'-phenylethoxy) quinine quinuclidine chloride and application of the medical composition in preparing drugs for treating chronic obstructive lung disease, incontinentia urinae, diversified shock diseases and preparing adjuvant drugs used before anaesthesia. The active component of the medical composition of the invention has high optical purity, strong stereoselectivity in vivo process, definite curative effects and high pertinency to the disease, thus effectively avoiding generation of toxic and side effects.

The compound Chinese onion preparation for treating chronic obstructive lung disease is prepared with Chinese onion, trichosanthes peel, Chinese goldthread, immature bitter orange, cassia twig and other chinese medicine materials. The preparation process includes crushing material, ethanol extraction, depression recovery of ethanol, concentration, adding supplementary material, vacuum drying to obtain dry extract, crushing, and further steps to prepare tablet, capsule, drip pills and micro pills. The compound Chinese onion preparation has obvious functions of relieving cough, eliminating phlegm and relieving asthma, and may be used to treat chronic obstructive lung disease effectively. It is ideal medicine for COPD in acute stage and COPD in prolonged stage and chronic stage.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an antihistamine for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and / or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.

An inhaler device to treat obstructive lung disease has an immediate acting bronchodilator medication, a dispenser housing for dispensing the immediate acting bronchodilator medication, and indicia on the dispenser housing to convey to a user that the inhaler device contains inhaler medication for for acute relief of obstructive lung disease symptoms.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a leukotriene receptor antagonist for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

Belonging to the technical field of medicine food homology formula and new resource food, the invention specifically provides a non-total nutrient formula food, specific total nutrient formula food or total nutrient formula food for chronic obstructive pulmonary disease patients to eat. According to the requirements of ''general principles of formula food for special medical use'', the formula combines the physique characteristics of chronic obstructive pulmonary disease patients, a plurality of ''medicinal and edible'' traditional Chinese medicines are combined rationally according to the traditional Chinese medicine quintessence theory, multiple medicinal and edible Chinese herb extract essence extracted by prehydrolysis SBE technology, biological enzymolysis extracted short-peptide, prebiotics, amino acid, carbohydrate, grease with health care function, multivitamin and minerals are mixed and processed by other technologies to obtain the formula food. As a single nutrient source, the formula food meets the nutritional needs of chronic obstructive pulmonary disease patients, and also has the efficacy of clearing heat and eliminating phlegm, warming lung and dissipating excessive fluid, promoting blood circulation and removing stasis, activating stagnated yang and relieving stagnation, invigorating spleen and benefiting lung, invigorating lung and benefiting kidney, reinforcing qi and nourishing yin, and strengthening immunity.

The invention relates to a traditional Chinese medicine formula for treating lung and kidney qi deficiency syndrome of chronic obstructive pulmonary disease (COPD). The problem of the medicine for treating the lung and kidney qi deficiency patient in the stable period of COPD is effectively solved. The traditional Chinese medicine formula comprises 6-20mg ginseng extract, 10-100mg icariin, 1-8mg paeonol, 0.5-6mg nobiletin, 5-20mg paeoniflorin, 3-12mg schisandrin b, 1-8mg peimine, 5-20mg hesperidin, 3-12mg astragalus polysaccharide and 1-8mg astragaloside. The traditional Chinese medicine formula provided by the invention can be effectively applied to the treatment for the lung and kidney qi deficiency syndrome of chronic obstructive pulmonary disease and the preparation of the preparationthereof. Repeated test proves that the traditional Chinese medicine formula is capable of improving COPD lung function, relieving lung tissue pathological injury and inflammatory cell infiltration andimproving inflammatory response and oxidative stress and can be used as long-term used medicine in the stable period for treating COPD. The traditional Chinese medicine formula has the advantages ofreasonable composition, scientific method, high innovation, accurate curative effect and obvious economic and social benefits.

The invention relates to a preparation method and an application of a Magnolia flower volatile oil soft capsule for treating allergic rhinitis and associated diseases. The Magnolia flower volatile oil soft capsule contains the following ingredients in parts by volume: 1 to 90 parts of Magnolia flower volatile oil, 10 to 90 parts of oil phase, 0 to 50 parts of emulsifier and 0 to 30 of co-solvent. The Magnolia flower volatile oil soft capsule, provided by the invention, is also available in the form of an enteric-coated soft capsule, so as to reduce irritation to the stomach and enhance the patient compliance. The soft capsule provided by the invention is used for treating allergic rhinitis, acute rhinitis, simple rhinitis, hypertrophic rhinitis, atrophic rhinitis, acute nasosinusitis, chronic nasosinusitis or complications thereof, as well as respiratory diseases such as acute upper respiratory infection, acute / chronic obstructive lung disease and asthma, with remarkable curative effects.

The invention provides an application of licorice flavonoids in preparing medicine for treating acute and chronic lung inflammatory diseases. The acute and chronic lung inflammatory diseases comprise acute lung Injury, acute respiratory distress syndrome, severe acute respiratory organ syndrome, chronic obstructive lung disease, asthma and the like. The licorice flavonoids preparation provided by the invention has strong antiinflammatory action and can coordinate or replace the application of hormone in treating diseases including acute lung Injury, acute respiratory distress syndrome, severe acute respiratory organ syndrome, chronic obstructive lung disease, asthma and the like. Compared with the hormone, the licorice flavonoids enjoys the characteristics and advantages that adverse reactions are few, possibility of triggering drug induced disease is slim. Licorice flavonoids is extracted from natural plants and can be prepared into health food for playing a supplementary role in improving symptoms caused by diseases.

The present invention relates to procaterol preparation, and especially one new kind of procaterol dripping pill for treating bronchial asthma, asthma bronchitis and chronic obstructive lung diseases and its preparation process. The medicine releasing rate of procaterol may be regulated via selecting different dripping pill matrix, composition and coating material. The preparation may contain stabilizer and corrective, the dripping pill may have or have no coating, and the dripping pill may be held under tongue or orally taken with completely dissolving and dispersing time of 1-15 min. The present invention has simple preparation process, controllable quality, high stability and convenient use.

The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary / respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.

The invention provides an atomizing agent for treating the chronic obstructive pulmonary disease. The atomizing agent at least comprises at least one of choline, gentiopicroside, peimine, berberine and glycyrrhetinic acid. Research in the invention finds that active ingredients cooperate with each other, and the synergistic active ingredients are locally administrated in respiratory tracts and lungs through an atomization means, so that the effects of cleaning the airway, humidifying the airway, reducing infiltration of inflammatory cells, inhibiting release of interleukin and other cytokines,improving airway stenosis and remarkably improving the treatment effect can be achieved; moreover, the cell intolerance of local administration can be synergistically reduced; and the cytotoxicity can be remarkably reduced.

The invention provides a toxin-eliminating drug composition, a drug preparation and preparation methods of the drug composition and the drug preparation. The drug composition comprises the following components in parts by weight: 7-10 parts of dogbane, 15-18 parts of field sowthistle herb, 15-18 parts of dandelions and 3-5 parts of ginger, wherein dogbane has the functions of calming the liver, clearing heat, improving the eyesight and reducing internal heat and blood pressure; under the action of the drug dogbane, the content of nicotine in human bodies is reduced to some extent, thus reducing the harms of nicotine to human bodies; field sowthistle herb has the function of eliminating the toxicity of nicotine; the dandelions and ginger can be used for promoting the release of nicotine from the bodies and preventing and relieving such diseases caused by smoking as bronchitis, lung cancers, chronic obstructive lung diseases, atherosclerosis lesions and duodenal ulcer of smokers; therefore under the synergistic action of dogbane, field sowthistle herb, dandelions and ginger, the toxin-eliminating drug composition and drug preparation provided by the invention can be used for reducing the harms of nicotine to human bodies.

The invention discloses a whole-lung forced oscillation spectrum detection system composed of a vibration generator and an infrasound sensor which are mutually matched in use. The vibration generator is connected with an oral airway interface through a connecting pipe. The infrasound sensor is provided with a chest strap binding the chest of a patient. The whole-lung forced oscillation spectrum detection system further comprises a computer which is connected with the infrasound sensor. By the detection system which is taken as a supplement to lung functional test, diseases of chronic obstructive lung disease, asthma and the like can be more sensitively diagnosed, and detection performed in calm breathing with no need for cooperation of the patient can reflect the situation of the lung function of the patient, at different parts. The whole-lung forced oscillation spectrum detection system can be used for identifying respiratory diseases of the chronic obstructive lung disease and the asthma, evaluating the effect of the treatment, detecting early tumors and the like.

The invention provides a medical application of spearmint oil in preparation of medicaments for treating chronic obstructive pulmonary diseases. The spearmint is taken from labiatae mentha, is obtained by vapor distillation and rectification, and mainly contains 20-60% of limonene and 20-70% of carvone. The pharmacodynamics proves that the spearmint oil provided by the invention lowers the contents of lung tissue TNF (tumor necrosis factor)-alpha and IL-1 beta for lipopolysaccharide, inhibits the over-expression of MMP-9, has an effect on improving models of Klebsiella pneumoniae infection and rat chronic obstructive pulmonary diseases caused by LPS (lipopolysaccharide), has an effect on reducing expression enhancement of lung tissue Nrf2 protein of a COPD (chronic obstructive pulmonary disease) model, and lowers the content of lung tissue IL-8 and the expression of a CCR2 receptor. The spearmint oil provided by the invention is natural and nontoxic and can be used for preparing medicaments for treating chronic obstructive pulmonary diseases.

The invention discloses a traditional Chinese medicine auxiliary diagnosis and treatment method and system for a chronic obstructive pulmonary disease. The method comprises the steps: collecting symptom information of a patient with the chronic obstructive pulmonary disease; preprocessing the symptom information to obtain a traditional Chinese medicine symptom type result corresponding to the symptom feature vector; according to the traditional Chinese medicine syndrome type result, acquiring recommended drugs through judgment; then performing, by the user, corresponding intervention correction according to the traditional Chinese medicine syndrome type result and the recommended medicine; and recording the treatment process of the chronic obstructive pulmonary disease patient and ending the treatment. According to the method provided by the invention, the traditional Chinese medicine auxiliary diagnosis and treatment process of the chronic obstructive pulmonary disease is decomposed into two links of syndrome type judgment and drug recommendation, and the relevance among symptoms, syndrome types and drugs in a traditional Chinese medicine diagnosis and treatment data set of the chronic obstructive pulmonary disease is fully utilized in the construction process of the syndrome type judgment model and the drug recommendation model. Therefore, the auxiliary diagnosis and treatment information with a relatively good auxiliary effect is obtained.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The invention relates to the technical field of lung disease treatment, in particular to application of stem cell-derived exosomes in preparation of drugs for treating chronic obstructive pulmonary diseases. The research shows that the exosome which is small in structure and can be more easily taken by recipient cells has a treatment effect similar to that of stem cells in treatment of chronic obstructive pulmonary diseases, and is more easily taken by the recipient cells due to no immunological rejection, so that the exosome can be used as a substitute of the stem cells and can be used for treating chronic obstructive pulmonary diseases. A new thought and strategy are provided for treating the chronic obstructive pulmonary disease.